AG真人官方

Kazia Therapeutics (KZIA) filed a Form 6-K announcing an at-the-market (ATM) equity program with Rodman & Renshaw. The facility permits issuance of up to US$1.9 million in American Depositary Shares (each ADS = 500 ordinary shares) under an effective F-3 shelf. Rodman will act as sales agent on a commercially-reasonable-efforts basis for up to 3% commission; Kazia sets daily share limits, price floors and may end the agreement with 10-days鈥� notice.

Net proceeds are earmarked for general corporate purposes, including R&D, working capital and potential asset acquisitions. While the agreement adds funding flexibility, any ADS issuance will dilute existing holders.

The 6-K adds supplemental risk factors outlining regulatory and combination-therapy uncertainties for lead candidate Paxalisib and other pipeline assets.

Governance update: on 20 Dec 2024, CEO John Friend resigned from the board and as managing director to focus on his chief executive duties; the remaining four directors are independent.

Form 4 highlights: On 24-Jul-2025, SM Energy (SM) Senior Vice President 鈥� Business Development & Land Kenneth J. Knott reported insider equity transactions. A performance share unit (PSU) award vested, issuing 3,458 common shares to Knott (Code M). To satisfy tax withholding, 843 shares were disposed of at $24.71 each (Code F). His direct holdings after settlement total 134,235 common shares.

On 25-Jul-2025 Knott also received 15,361 restricted stock units (RSUs) that vest in six equal biannual installments starting 1-Jan-2026. Each RSU converts to one common share upon vesting, bringing his derivative holdings to 15,361 RSUs.

The net effect is an incremental 2,615-share increase in direct ownership, modestly reinforcing management-shareholder alignment. Given SM鈥檚 large public float, the dollar value is immaterial at the corporate level, implying limited market impact.

Rubric Capital Management LP, an investment adviser headquartered in New York, and its managing member David Rosen jointly filed Amendment No. 2 to Schedule 13G on 07 July 2025 regarding their holdings in Ovid Therapeutics Inc. (OVID).

• Beneficial ownership: 478,533 common shares.
• Ownership percentage: 0.67 % of the 71,109,514 shares outstanding as of 19 May 2025 (per the issuer鈥檚 latest proxy).
• Voting & disposition rights: 0 shares sole voting/dispositive power; 478,533 shares shared voting and shared dispositive power.
• Reporting persons: Rubric Capital (investment adviser) and David Rosen (individual, control person).
• Filing trigger date: 30 June 2025; the position is now below the 5 % threshold, leading to a 鈥淥wnership of 5 percent or Less鈥� disclosure.
• Certification: Securities held in the ordinary course and not for the purpose of influencing control.

The filing is informational, confirming a modest (<1 %) stake by Rubric Capital without indicating any intent to alter the company鈥檚 control or strategy.

Kazia Therapeutics Limited (NASDAQ: KZIA) has filed a Rule 424(b)(3) prospectus supplement dated 9 July 2025 to incorporate a newly furnished Form 6-K into its December 2 2024 prospectus. The supplement attaches a 6-K that contains a press release reporting first鈥恑n-human preliminary efficacy data from the company鈥檚 ongoing Phase 1b study evaluating paxalisib + pembrolizumab + chemotherapy in metastatic triple-negative breast cancer (TNBC).

• Patient profile: 61-year-old woman with lung-localized metastatic TNBC.
• Day-21 outcome (end of cycle 1): >50 % reduction in total circulating tumor cells (CTCs) and comparable decline in CTC clusters; decrease in mesenchymal phenotype of residual CTCs.
• Clinical context: CTC clusters are 20鈥�100脳 more efficient at establishing metastases than single CTCs; standard chemotherapy alone often increases CTC counts in early cycles, underscoring the significance of the observed rapid decline.
• Strategic significance: Data echo pre-clinical findings published in Molecular Cancer Therapeutics, suggesting mechanistic synergy of paxalisib with immunotherapy. Enrollment in the Phase 1b trial continues, with plans for serial CTC and immune-micro-environment monitoring.
• Capital markets context: The filing registers 95,111 ADSs (representing 47,555,560 ordinary shares). The ADSs last traded at US$6.825 on 8 July 2025.

Investors should note that results stem from a single patient and remain subject to the usual clinical-development, regulatory and marketplace risks highlighted in the company鈥檚 risk-factor disclosures.

Ryde Group Ltd (NYSE American: RYDE) has filed a Form F-3 shelf registration to give itself maximum flexibility to raise capital over the next three years.

• Primary shelf: up to US$100 million in Class A ordinary shares, debt securities, warrants, rights or units that may be sold directly, or through underwriters, dealers or agents.
• Rule 415 eligibility: the company鈥檚 public float is only US$4.768 million (14.9 million non-affiliate shares at US$0.32 on 7 Jul 2025). Under Instruction I.B.5, Ryde cannot sell more than one-third of that float (鈮圲S$1.6 million) in any 12-month period until its market value exceeds US$75 million.
• Carry-over securities: (i) 5.3 million Class A shares issuable on exercise of warrants sold in the Sept 2024 follow-on offering; (ii) conversion of the prior Form F-1 registration (File No. 333-282076) into the new shelf.
• Resale component: 8.03 million Class A shares held by Octava Fund Ltd may be offered for secondary sale. Ryde will receive no proceeds.

The filing refreshes capital-raising capacity after a series of corporate actions:

• US$12 million IPO (Mar 2024) and US$4.5 million follow-on (Sept 2024).
• Secondary listings on Frankfurt and Stuttgart (Jun 2024) and several new subsidiaries (BVI and Singapore) to support expansion.
• 40 % stake in Atoll Discovery (Jun 2025) paid with 4.85 million Ryde shares.

Business snapshot. Ryde is a Cayman Islands holding company whose operating subsidiaries in Singapore run a 鈥渟uper mobility app鈥� offering car-pooling, ride-hailing (RydeX, RydeXL, RydeLUXE, RydePET, RydeTAXI) and quick-commerce parcel delivery (RydeSEND). Key strengths cited include dual-segment platform, scalable technology and experienced management.

Key risks spelled out in the prospectus:

• Early-stage growth and continuing losses; profitability hinges on reducing driver/consumer incentives.
• Intense competition from Grab, Gojek, ComfortDelGro, Lalamove and others.
• Regulatory overhang (Platform Workers Act 2024, driver classification, data privacy, AML, LTA licensing).
• Micro-cap status (US$0.32 share price), potential NYSE American listing compliance challenges and dilution from warrants, resale shares and future offerings.
• Technology, cybersecurity and brand-reputation risks inherent in ride-hailing and delivery models.

Use of proceeds will be detailed in future prospectus supplements, but typical purposes include working capital, technology investments and potential acquisitions. The company鈥檚 ability to tap the full US$100 million depends on a significant improvement in market capitalization or uplisting.

Overall, the F-3 positions Ryde to raise incremental capital quickly, continue warrant coverage and permit shareholder liquidity, while highlighting substantial competitive, operational and regulatory headwinds that investors must weigh.

Schedule 13G Filing Overview: Tong Wu has filed a Schedule 13G indicating passive beneficial ownership of Armlogi Holding Corp. (CUSIP 042255109) common stock.

• Shares held: 3,460,000
• Ownership percentage: 8.2 % of the 42,250,934 shares outstanding as of 30 June 2025
• Voting & dispositive power: Sole power over all reported shares; no shared power
• Filing type: Rule 13d-1(c) passive investor report (Schedule 13G)
• Event date: 30 June 2025鈥�Signature date: 09 July 2025

This filing signals that Mr. Wu has crossed the 5 % threshold and now ranks among the company鈥檚 largest shareholders. No additional transactions, purchase prices, or strategic intentions are disclosed, and the filer certifies the information as true and complete.